CLINICAL TRIALS PROFILE FOR ZEVALIN
✉ Email this page to a colleague
All Clinical Trials for ZEVALIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00038623 ↗ | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma | Completed | Biogen | Phase 2 | 2002-04-01 | Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed & Refractory Mantle Cell Lymphoma |
| NCT00038623 ↗ | Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma | Completed | M.D. Anderson Cancer Center | Phase 2 | 2002-04-01 | Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed & Refractory Mantle Cell Lymphoma |
| NCT00048737 ↗ | Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | Completed | Biogen | Phase 1/Phase 2 | 2002-10-01 | The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of remission in patients with leukemia and lymphoma. The safety of this treatment will also be studied. |
| NCT00048737 ↗ | Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | Completed | M.D. Anderson Cancer Center | Phase 1/Phase 2 | 2002-10-01 | The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of remission in patients with leukemia and lymphoma. The safety of this treatment will also be studied. |
| NCT00057343 ↗ | Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma | Terminated | Biogen | Phase 3 | 2003-03-01 | The purpose of this study is to provide treatment for patients who have relapsed NHL or refractory NHL, and to determine the effectiveness and safety of the Zevalin and Rituxan regimens or Rituxan therapy alone on your disease. |
| NCT00058422 ↗ | Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | Completed | National Cancer Institute (NCI) | Phase 2 | 2003-02-10 | RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab and combination chemotherapy with yttrium Y 90 ibritumomab tiuxetan in treating older patients who have B-cell lymphoma that has not been previously treated. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ZEVALIN
Condition Name
Clinical Trial Locations for ZEVALIN
Trials by Country
Clinical Trial Progress for ZEVALIN
Clinical Trial Phase
Clinical Trial Sponsors for ZEVALIN
Sponsor Name
